Reports Q2 revenue $54.8M consensus $52.0M. “In a highly dynamic macroenvironment, our ability to deliver solid second quarter results and maintain our 2025 revenue growth guidance is a testament to our strong customer relationships and the demand for proven computational technologies to accelerate molecular discovery,” said Ramy Farid, Ph.D., chief executive officer of Schrodinger (SDGR). “In addition to progressing several collaborative programs in our pipeline, we achieved an important milestone with the presentation of encouraging initial data for our MALT1 inhibitor, SGR-1505, and we expect to report initial data from our other two clinical programs in the fourth quarter.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SDGR:
- Meta upgraded, PNC Financial downgraded: Wall Street’s top analyst calls
- Schrodinger assumed with an Equal Weight at Morgan Stanley
- Schrodinger Announces Board Elections and Approvals
- Positive Outlook for Schrödinger: Promising Phase 1 Data and Strategic Growth Initiatives Support Buy Rating
- Schrodinger’s Promising Clinical Data Offset by Market Concerns: Hold Rating Maintained